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Purpose: A retrospective study of radiation-induced apoptosis in CD4 and CD8 T-lymphocytes, from 12 cancer
patients who displayed enhanced toxicity to radiation therapy and 9 ataxia telangiectasia patients, was performed
to test for altered response compared to healthy blood-donors and normal cancer patients.
Methods and Materials: Three milliliters of heparinized blood from each donor was sent via express post to the
Paul Scherrer Institute (PSI) for subsequent examination. The blood was diluted 1:10 in RPMI medium,
irradiated with 0-, 2-, or 9-Gy X-rays, and incubated for 48 h. CD4 and CD8 T-lymphocytes were then labeled
using FITC-conjugated antibodies, erythrocytes were lysed, and the DNA stained with propidium iodide.
Subsequently, cells were analyzed using a Becton Dickinson FACScan flow cytometer. Radiation-induced
apoptosis was recognized in leukocytes as reduced DNA content attributed to apoptosis-associated changes in
chromatin structure. Apoptosis was confirmed by light microscopy, electron microscopy, and by the use of
commercially available apoptosis detection kits (in situ nick translation and Annexin V). Data from hypersen-
sitive individuals were compared to a standard database of 105 healthy blood-donors, and a database of 48 cancer
patient blood donors who displayed normal toxicity to radiation therapy. To integrate radiosensitivity results
from CD4 and CD8 T-lymphocytes after 2 and 9 Gy, z-score analyses were performed.
Results: A cohort of 12 hypersensitive patients was evaluated; 8 showed enhanced early toxicity, 3 showed
enhanced late toxicity, and 1 showed both. The cohort displayed less radiation-induced apoptosis (21.8 s) than
average age-matched donors. A cohort of 9 ataxia telangiectasia homozygotes displayed even less apoptosis (23.6
s).
Conclusion: The leukocyte apoptosis assay appears to be a useful predictor of individuals likely to display
increased toxicity to radiation therapy; however, validation of this requires a prospective study. © 1999 Elsevier
Science Inc.
Normal tissue toxicity, Radiation-induced apoptosis, Ataxia telangiectasia, Concomitant chemotherapy, Lym-
phocytes.
INTRODUCTION
Development of predictive assays for clinical prediction
requires that the diagnostic test employed display both high
reproducibility and low variation (1). With the development
of the leukocyte apoptosis assay to identify individuals
genetically predisposed to radiation injury, both of these
parameters were carefully considered. We have developed
an assay employing a triple variation-minimizing strategy;
flow cytometric blood analysis, gentle fixation, and cumu-
lative apoptosis. By employing flow cytometric blood anal-
ysis 10,000 cells or more can be rapidly and objectively
assessed for the parameter of interest (2). More importantly,
a number of different cell types can be investigated, which
enhances the specificity of the assay, giving the clinician
additional confidence in results from samples which deviate
from normality (3). Because apoptosis is the biological
endpoint measured, use of a gentle fixation procedure en-
sures that the fragile apoptotic cells are not being lost during
the work-up. Although the process of apoptosis in many cell
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types is short-lived, lymphocytes in cell culture display an
“arrested” apoptosis after radiation exposure. The cells re-
main in this state for many days, and accumulation of the
apoptotic cells leads to large signal-to-noise ratios. We have
also developed an assay employing a triple-enhanced repro-
ducibility strategy; robust handling, standardized compo-
nents, and a simple, optimized procedure. The assay is
robust to handling. Subsequent to venipuncture, the periph-
eral blood lymphocytes can be left at room temperature for
72 h and can be readily transported in the mail. The com-
ponents used are all commercially available and are all
standard materials used for blood handling or flow cytom-
etry. In addition, the assay is a relatively straightforward
assay that is not burdened by critical procedures.
We have previously demonstrated that the population of
dead cells evaluated was apoptotic (4, 5). The cells display
a small size with a reduced propidium iodide signal. This
has been previously reported in the literature, and is typical
of apoptotic cells in general (6–8). The cells are whole, but
their membranes are permeable. Using light and electron
microscopy methods, an ultrastructure typical for apoptotic
cells, as described in the literature, is observed (9, 10). The
nuclei contain condensed chromatin, and large vacuoles are
visible in the cytoplasm (11). Biochemical analyses reveal
the cells to be both TUNEL- and ANNEXIN V-positive (5).
Further indications that what we were measuring were truly
apoptotic cells have also been described in the literature,
and include: (a) that this was by far the major form of
radiation-induced cytotoxicity observed after radiation (12–
14), that lymphocytes from patients displaying ataxia telan-
giectasia display reduced yields of apoptosis (15–17), and
that lymphocytes from umbilical cord blood display en-
hanced yields of apoptosis (18).
The various leukocyte cell types display clear differences
in radiosensitivity (4, 19). Of the cell types investigated,
monocytes were the most radioresistant, displaying little
difference to background noise. The assay has been used to
monitor apoptosis in granulocytes, and we have used it to
monitor the health of granulocytes in novel bone marrow
transplantation protocols (20). Of the lymphocyte cell types
examined, CD8 T-lymphocytes appear the most sensitive;
however, some individuals tested displayed similar CD8
and CD4 T-lymphocyte apoptosis yields (4). Differences in
yields between the lymphocyte cell types are heavily de-
pendent on the genotype of the individual, as we have
demonstrated for patients with ataxia telangiectasia and
immunodeficiency, centromeric instability, and facial
anomalies (ICF) syndrome. Gender differences appeared to
have no effect on the apoptotic yield; however, donor age
did make a difference. Although originally described after
24 h post-incubation, little statistical significance could be
attached to these early studies (5). With subsequent optimi-
zation of the assay, the analyses were performed 48 h after
irradiation, and we report here a highly significant depen-
dence on age of apoptotic yield. In this double-blind cross-
sectional study, we investigated radiation-induced apoptosis
in T-lymphocytes from various cohorts of blood donors:
healthy donors, normal cancer patients, cancer patients hy-
persensitive to radiotherapy, and ataxia telangiectasia ho-
mozygotes who are highly sensitive to ionizing radiation
(15).
METHODS AND MATERIALS
Blood samples were collected from various sources. All
blood samples were collected under consent and were trans-
ported to the Paul Scherrer Institute in heparin tubes at room
temperature using conventional postal options. Usually,
blood was examined within 48 h of venipuncture; rarely, it
was examined 72 h later. The Swiss Red Cross provided
blood samples from 105 healthy donors (average age 47.2
years, range 21–73). For the cancer patient cohort, 48 sam-
ples were received from a single clinic in Switzerland
(average age 71.9 years, range 30–89). To collect a cohort
of hypersensitive patients, request for assistance was made
to the various radiation oncology departments in Switzer-
land. A total of 12 samples were accrued via four major
centers. The average age of the patients was 55 years, with
a range of 41–75. A standardized, confidential questionnaire
was completed by the referring physician, which provided
pertinent data concerning patient diagnosis, hypersensitive
reaction, radiotherapy, concomitant chemotherapy, and
probe accrual for each of the hypersensitive patients. For
logistic reasons, blood from 2 hypersensitive patients (case
numbers 3 and 8) were examined within 72 h of venipunc-
ture. Blood samples from 9 ataxia telangiectasia homozy-
gotes (average age 7.6 years, range 4–11.5), were provided
from the Immunology Division, Hacettepe Children’s Hos-
pital, Ankara, Turkey. These samples were transported by
air and were all examined within 48 h of venipuncture.
Details of the leukocyte apoptosis assay have been pre-
viously described (21). Briefly, heparinized whole blood
(3.6 ml) was diluted to a 1:10 concentration in RPMI 1640
medium (Life Technologies, Basel, Switzerland) containing
20% FBS, and the cells were treated with 0-, 2-, and 9-Gy
X-rays (Philips MCN 321 x-ray tube, Hamburg, Germany;
300 kVp, 10.65 mA, 3.4 Gy/min). Dosimetry was per-
formed using a Farmer dosimeter 2570 (Nuclear Enter-
prises, Zurzach, Switzerland; exact doses measured were
2.34 and 9.01 Gy). After 48 h, cells were harvested and
treated for 20 min with either CD4 or CD8 FITC-conjugated
monoclonal antibodies (Becton Dickinson, Basel, Switzer-
land); 10 ml antibody suspension were added to 200-ml cell
suspension. To promote lysis of the erythrocytes and per-
meabilization of leukocytes, the cell suspensions were in-
cubated for 10 min at room temperature in a 4:1 diethyl-
eneglycol:formaldehyde buffered solution (FACS Lysing
Solution, Becton Dickinson, Basel, Switzerland). The cells
were then washed, centrifuged, and resuspended in 200 ml
phosphate buffer (FACS Flow, Becton Dickinson) with 5
ml of 1 mg/ml PI and 50 ml of 1 mg/ml RNase (Bovine
pancreas RNase A, Serva, Heidelberg, Germany). The cells
were subsequently examined in the flow cytometer.
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To detect treatment-induced apoptosis, multiparameter
data acquisition of the cell sample was performed using a
FACScan flow cytometer (Becton Dickinson, San Jose, CA)
with a 488 nm, 15 mW argon-ion laser (Coherent, Santa
Clara, CA). Data from each lymphocyte sample were ac-
quired immediately after the staining procedure. A two-
dimensional dot-plot of antibody-fluorescence (FL1-height)
versus cellular DNA content (FL2-height) was used to iden-
tify the CD4- or CD8-positive lymphocytes. A two-dimen-
sional dot-plot of cellular DNA content (FL2-height) versus
cell size (FSC-height) was used to determine the proportion
of apoptotic cells by identifying the population of cells with
reduced DNA content and slightly reduced cell size. The
two populations could always be distinguished. The apo-
ptotic cells had a significantly reduced (approximately
5-fold, compared to non-apoptotic cells) DNA fluorescence.
This 5-fold reduction remained constant over many days,
and is attributed to chromatin condensation associated with
the process of apoptosis (21). Radiation-induced apoptosis
was calculated by subtracting the background level (0 Gy)
of apoptotic cells from the total measured. Data are pre-
sented in this form, or age-weighted (by subtracting the
expected apoptotic yield based on the regression curve of
age versus apoptosis), or age-weighted as z-scores (standard
deviation, s, units from the mean).
RESULTS
To have a baseline with which to compare radiation-
induced apoptosis in T-lymphocytes from patients display-
ing enhanced toxicity to radiation therapy, it was necessary
to screen at least 100 healthy blood donors, using the
leukocyte apoptosis assay. Interdose comparisons of the
percent apoptosis induced by 2- and 9-Gy X-rays in CD4
T-lymphocytes from a cohort of 105 healthy Red Cross
blood donors (average age 47.2 years; 29 females, 76 males)
are displayed in Fig. 1. A strong correlation was observed
(r 5 0.9) for CD4 T-lymphocytes. The data are presented
with the background (0 Gy) apoptosis levels subtracted. A
similar analysis of the CD8 T-lymphocytes resulted in r 5
0.74. The background levels of apoptosis for the two cell
types averaged 4% and 4.8% for the CD4 and CD8 T-
lymphocytes, respectively. No correlation between back-
ground apoptosis and radiation-induced apoptosis was ob-
served, as previously reported (5). The levels of apoptosis
observed after 9-Gy X-rays in the CD4 and CD8 T-lym-
phocytes are compared in Fig. 2. The regression line has the
formula y 5 0.79x 2 0.39, r 5 0.77. The correlation
between radiation-induced apoptosis in CD4 T-lymphocytes
and age of donor is displayed in Fig. 3. Included are two
cohorts of donors; the 105 Red Cross donors and 48 cancer
patient donors whose average age was almost 20 years
Fig. 1. Interdose comparison of the percent apoptosis induced by
2- and 9-Gy X-rays in CD4 T-lymphocytes from a cohort of 105
healthy Red Cross blood donors. The background levels (0 Gy) of
apoptosis were subtracted.
Fig. 2. Interleukocyte comparison of the percent apoptosis induced
by 9-Gy X-rays in CD4 and CD8 T-lymphocytes from a cohort of
105 healthy Red Cross blood donors. The background levels (0
Gy) of apoptosis were subtracted.
Fig. 3. Percent apoptosis induced by 9-Gy X-rays in CD4 T-
lymphocytes as a function of age of blood donor. Open circles 5
data from a cohort of 105 healthy Red Cross blood donors; filled
squares 5 data from a cohort of 48 non-hypersensitive cancer
patients. The background levels (0 Gy) of apoptosis were sub-
tracted.
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older. The regression line has the formula y 5 63.5 2
0.65x, r 5 0.78.
Figure 4 compares levels of apoptosis induced by 9-Gy
X-rays in the CD4 and CD8 T-lymphocytes after the con-
tribution of age has been accounted for. The expected apo-
ptotic value, based on patient age, was subtracted from the
value observed. Data from both the 105 healthy donor
cohort and the 48 cancer patient donor cohort were in-
cluded. The regression lines have the formula y 5 0.56x 2
0.43, r 5 0.69; and y 5 0.49x 2 1.06, r 5 0.65, for the
healthy donors and cancer patient donors, respectively. No
significant differences between the two cohorts were ob-
served. Using this combined cohort of 153 normal respond-
ers, comparison was made with 21 abnormal responders.
The data are presented in Fig. 5. Use of z-scores (number of
standard deviations from the mean) was made in order to
pool data from both 2- and 9-Gy exposures. The response of
the CD4 T-lymphocytes is compared with the response of
the CD8 T-lymphocytes. Results from three cohorts of
donors are displayed; a combined cohort of 153 normal
responders, a cohort of 12 hypersensitivity patients (6 fe-
males, 6 males), and a cohort of 9 ataxia telangiectasia
homozygotes.
Figure 6 is a “high-resolution” graph of the hypersensi-
tive cohort response. The apoptotic yield of each patient can
be examined in this figure. The z-score data were weighted
for age; however, less than normal levels of radiation-
induced apoptosis were observed in all of these patients.
The average CD8-apoptotic z-score of these patients is
1.8 6 0.66 standard deviation below the expected mean
predicted from the 153 normal responder cohort. To deter-
mine levels of significance (p-values) when comparing the
normal responder cohort (n 5 153) with the hypersensitive
cohort (n 5 12), difference-of-means tests were performed.
t-scores were determined because there were less than 30
individuals in the hypersensitive cohort. Both CD4 and CD8
T-lymphocyte responses were examined; CD4 T-lympho-
cytes: t 5 4.96, p , 0.0001; CD8 T-lymphocytes: t 5 6.71,
p , 0.0001. The apoptotic response of T-lymphocytes from
hypersensitive patients is significantly different to the re-
sponse of T-lymphocytes from normal individuals.
Table 1 shows the details of the 12 hypersensitive pa-
tients and their treatment. The patients are listed in order of
increasing apoptotic response based on their average CD4
and CD8 z-scores. The age of the hypersensitive patients
Fig. 4. Age-independent levels (percent) of apoptosis induced by
9-Gy X-rays in the CD8 and CD4 T-lymphocytes. Open circles 5
data from a cohort of 105 healthy Red Cross blood donors; filled
squares 5 data from a cohort of 48 non-hypersensitive cancer
patients. The expected contribution of age, as determined from the
regression formula derived from Fig. 3, was subtracted.
Fig. 5. Apoptotic response of CD8 T-lymphocytes compared with
the response of CD4 T-lymphocytes. Results from three cohorts of
donors are displayed; 1 symbols 5 a combined cohort of 153
(105 1 48) normal responders; filled circles 5 a cohort of 12
enhanced radiosensitivity patients; large X symbols 5 a cohort of
9 ataxia telangiectasia homozygotes. The expected contribution of
age was subtracted and the data are presented as z-scores (number
of standard deviations from the mean).
Fig. 6. Apoptotic response of CD8 T-lymphocytes compared with
the response of CD4 T-lymphocytes. Results from the cohort of
cancer patients who displayed enhanced radiosensitivity. These
data are also displayed, at lower resolution, in Fig. 5. The num-
bered symbols refer to individual patients and are taken from Table
1. The expected contribution of age was subtracted and the data are
presented as z-scores (number of standard deviations from the
mean).
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ranged from 41.9 to 75.3 years (average 55 years). The ratio
of the sexes was equal. Four breast cancer cases (one male),
three rectal cancer cases, and two lung cancer cases are
reported. An esophageal cancer case, a head and neck
cancer case, and a glioblastoma case are also reported. In no
cases were related comorbidities present. In case numbers 1,
4, 7, 9, 10, and 12, very severe early reactions were ob-
served, and therapy was prematurely terminated. In the two
cases of severe early reactions where therapy was not
stopped, in case number 8 the patient subsequently died,
probably related to therapy-associated pulmonary compli-
cations (interstitial pneumonitis), and in case number 11, the
patient subsequently displayed a severe late reaction: Blind-
loop syndrome, for several years. Eventually, this patient
relapsed and was diagnosed with metastatic mediastinal
lymphadenopathies. Treatment of the metastases involved
chemotherapy and subsequent radiotherapy, and after 26
Gy, a blood sample was sent for testing. The patient devel-
oped severe dysphagia and severe esophagitis. In three other
cases (case numbers 2, 5, and 6), severe late reactions also
developed. Patient number 2 developed an ileal occlusion
and patient number 6 developed rectovaginal fistulae; both
required surgery. In case number 5, a brain radionecrosis
was observed following conformal proton therapy. Total
radiation doses administered and doses per fraction for all
hypersensitive patients are listed in Table 1.
Concomitant chemotherapy was performed on 6 of the
hypersensitive patients. In one case (number 2), chemother-
apy extended beyond the end of radiotherapy. In case num-
ber 11, the patient received external radiotherapy, brachy-
therapy, and concomitant chemotherapy. More than 5 years
later, when the blood sample was taken, metastases were
being treated with chemotherapy (gemcitabine) and subse-
quent radiotherapy. The background level of apoptosis ob-
served in this case was elevated, presumably as a conse-
quence of the second chemotherapy. Background levels (0
Gy) of apoptosis in T-lymphocytes were strongly influenced
by chemotherapy. In 6 of 6 patients treated with chemother-
apy, the average background level of apoptosis was 24.47 6
15.77% (range 13.63–55.18), 5-fold greater than expected.
In 6 of 6 patients treated with radiotherapy alone, the
average background level of apoptosis was 4.93 6 2.45%
(range 1.49–8.09), which is identical to average back-
ground levels in the normal responder cohort: 4.95 6
1.93%. These normal background levels were observed
from 0.4 to 12.4 months after completion of radiotherapy,
Table 1. Hypersensitive patient data












1 54.3 a Male Esophageal carcinoma Severe skin & dysphagia
reactions
43.2 1.8 5-FU, cis-Pt 0.9 mo 13.63
2 51.7 a Male Rectal carcinoma* Severe late reaction,
ileal occlusion†
50.4 1.8 5-FU 16.5 mo 55.18
3 41.9 a Female Left breast cancer* Myocardial infarct‡ 50.0 2.0 5-FU, Epi, CP 0.5 mo 13.96
4 43.8 a Female Lung cancer Severe erythema (Stevens-
Johnson synd.)
30.0 2.0 cis-Pt, Vinbl. 0.2 mo 16.98
5 54.2 a Female Glioblastoma* Brain radionecrosis (late
reaction)
60.0 2.0 None 12.4 mo 1.49
6 45.8 a Female Rectal carcinoma* Severe late reaction,
rectovaginal fistulae†
41.6 1.6\ None 5.5 mo 8.09
7 67.0 a Male Lung cancer Severe skin &
esophagitis reactions
36.0 2.0 None 7.0 mo 7.25
8 75.3 a Male Right breast cancer¶ Severe skin &
pneumonitis reactions
58.0 2.0 5-Fu, Dox, CP 2.5 mo 20.89
9 58.8 a Female Left breast cancer* Skin desquamation 66.0 2.0 None 0.4 mo 4.41
10 70.9 a Female Right breast cancer Severe radiation
dermatitis
54.0 2.0 None 7.0 mo 3.32
11 54.4 a Male Rectal carcinoma* Severe skin & late
enteropathy reactions
45.0# 1.8 5-FU, Mit C 68.2 mo 26.20
12 42.2 a Male Adenoid cystic
carcinoma
Severe skin & mucositis
reactions
55.0 2.25 None 0.6 mo 5.03
5-FU 5 5-fluorouracil; cis-Pt 5 cis-platin; Epi 5 Epirubicin; CP 5 cyclophosphamide; Vinbl 5 vinblastin; Dox 5 doxorubicin; Mit C 5
Mitomycin C.
§ Average CD4 and CD8 background (0 Gy) apoptosis (%).
* Radiotherapy completed.
† Required surgery.
‡ Infarct developed during the third week of postoperative radiotherapy.
\ 2 fractions per day.
¶ Male breast cancer.
# 45.0 Gy external therapy and 25.0 Gy brachytherapy, 5 years later the patient received chemotherapy and radiotherapy to treat
metastases.
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and were independent of whether the patients displayed
severe early or severe late reactions. These data indicate that
treatments based on radiotherapy with concomitant chemo-
therapy are more noxious, at least to T-lymphocytes, than
treatments based on radiotherapy alone.
Although hypersensitive patients who received concom-
itant chemotherapy tended to display less radiation-induced
apoptosis than hypersensitive patients who received radio-
therapy alone, a difference-of-means test performed to com-
pare radiation-induced apoptosis revealed that at the 10%
significance level it was not possible to distinguish between
the two groups; t 5 1.75, p . 0.1. The 5-fold enhanced
background levels of apoptosis do not significantly influ-
ence subsequent apoptotic response to the radiation doses
employed in the leukocyte apoptosis assay. Difference-of-
means tests were also performed to compare the radiation-
induced apoptotic response of these two hypersensitive
groups with that of the normal responder cohort. The com-
parison with patients receiving radiotherapy alone yielded
t 5 2.71, p , 0.0017 and t 5 3.81, p , 0.0001 for CD4 and
CD8 T-lymphocytes, respectively; and the comparison with
patients receiving concomitant chemotherapy yielded t 5
3.70, p , 0.0001 and t 5 5.77, p , 0.0001 for CD4 and
CD8 T-lymphocytes, respectively. The radiation-induced
apoptotic responses of the CD4 and the CD8 T-lymphocytes
from both groups of hypersensitive patients are significantly
lower than the responses of the CD4 and the CD8 T-
lymphocytes from normal individuals.
DISCUSSION
Variation is inherent in any biological response assay. It
was, therefore, important to determine the reliability of the
assay (1). A first estimate of the biological variation of the
assay was determined by evaluating the correlation between
radiation-induced apoptosis after 2 and 9 Gy exposures. For
the CD4 cells, the correlation was highly significant, Pear-
son’s correlation coefficient r was 0.90. For the CD8 T-
lymphocytes this was somewhat lower, r 5 0.74. Statistical
analysis using Fischer’s transformation of r-scores to z-
scores confirms that the r-scores were significantly different
even at the 0.01% level. The reasons for the differences in
correlation between the two cell lines is not immediately
apparent. It may be that different subsets of CD8 T-lym-
phocytes display different radiosensitivities and that this
contributes to enhanced variation. Comparison of radiation-
induced apoptosis after 9 Gy in CD4 cells with radiation-
induced apoptosis after 9 Gy in CD8 cells yields a Pearson’s
correlation coefficient of 0.77. There is no significant dif-
ference between this value and the one from the CD8
interdose comparison. This indicates that, besides inherent
intra-cell-type variation, the information for predicting ra-
diosensitivity gained by analyzing radiation-induced apo-
ptosis in either CD4 or CD8 T-lymphocytes is essentially
identical. The slope of the curve in Fig. 2 is less than 1; CD8
T-lymphocytes display on average 25% more apoptosis than
CD4 T-lymphocytes.
Radiation-induced apoptosis was observed to display a
significant correlation with age. This correlation is dis-
played in Fig. 3. The data are from two cohorts of patients
from two different cities; a cohort of 105 healthy Red Cross
blood donors (Zurich), and a cohort of 48 cancer patient
donors (Basel). The data indicate that with each 10 years of
life, a dose of 9 Gy X-rays to CD4 T-lymphocytes induces
6.5% less apoptosis. The older people get, the less able their
T-lymphocytes are to mount an apoptotic response to ion-
izing radiation damage. The lymphocytes were irradiated ex
vivo, in blood diluted 10-fold by RPMI medium, which
suggests that age-dependent radiosensitivity is an autono-
mous feature of T-lymphocytes. Effros (22) reported that
aging in vivo is associated with an increasing frequency of
T-lymphocytes displaying characteristics typical of senes-
cent T cells in culture: shortened telomeres, a loss of CD28
cell surface expression, and an inability to proliferate. She
reported that replicative senescence in T-lymphocytes re-
duces apoptotic response to a variety of stimuli and is
associated with increased accumulation of the anti-apoptotic
protein Bcl-2. We are investigating whether these findings
are the reason for the age-dependent reduction in apoptosis
we have observed.
We also examined if the presence of a tumor in a patient
interferes with the radioresponsiveness of the T-lympho-
cytes by comparing the response of the two cohorts (see Fig.
4). The contribution of age, predicted from the regression
formula determined from Fig. 3, was subtracted. In the
healthy blood donor cohort, after subtraction of the age
contribution, Pearson’s correlation coefficient was observed
to have fallen from 0.77 to 0.69. This indicates that, al-
though age contributes to T-lymphocyte radiosensitivity, it
is not the only factor involved. No significant difference
between the healthy donor cohort and the cancer patient
cohort was observed. Independent of whether the contribu-
tion of age was estimated based on the regression curve of
the data from the healthy blood donor cohort alone or from
both cohorts together, after the contribution of age had been
subtracted, no difference between the two cohorts was ob-
served. The data suggest that the presence of a tumor in a
patient does not affect the radiosensitivity of the CD4 or
CD8 T-lymphocytes. The presence of a tumor may cause
shifts in the relative ratios of leukocyte cell-types, which
could result in an apparent change in total lymphocyte
response. However, there is no evidence for a systematic
release of either pro-apoptotic or anti-apoptotic immuno-
modulators from the tumors which is capable of altering the
radiosensitivity of the T-lymphocyte cell-types.
A clear difference in the sensitivity of CD4 and CD8
T-lymphocytes was observed in individuals who displayed
enhanced toxicity to radiation treatment. All of these blood
samples displayed less than expected apoptosis. The aver-
age CD8 T-lymphocyte apoptotic response of these 12
hypersensitive individuals was 1.8 s (z-scores) below the
average of the 153 normal responder cohort. Only one
individual from the normal responder cohort, but 50% of the
individuals from the hypersensitive cohort, displayed less
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apoptosis than 21.8 s. This difference was observed de-
spite the problem of overlapping population distributions
associated with this type of study, which tends to reduce the
significance of the data. Some individuals who display an
apparently hypersensitive reaction will lie at the extremes of
the normal responder distribution, where the populations
overlap. Testing these individuals for radiation-induced ap-
optosis will result in a normal response, and their inclusion
in the hypersensitive cohort will tend to reduce the numer-
ical significance of the data. It is hoped that an ongoing
prospective study will help to define the magnitude of this
problem. The reduced apoptosis observed in T-lymphocytes
from the hypersensitive individuals supports our hypothesis
that such individuals are unable to mount a normal, physi-
ological response to ionizing radiation, and this results in a
more severe, pathological reaction (5).
Various causes of differences in radiosensitivity are
known, both genetic and epigenetic (23, 24). The data
demonstrate two immediate sources of differences in apo-
ptotic response which can be classified as epigenetic: cell
type and donor age. As a first assumption, the genotypes of
an individual’s leukocytes are identical. Nevertheless, radi-
osensitivities of the different cell types are markedly differ-
ent, and even amongst lymphocytes, differences in radio-
sensitivities are observed (4, 19, 25). This emphasizes an
important aspect of radiation reactions. Although they are
dependent on physical characteristics such as dose, dose
rate, and radiation quality, they are also highly dependent on
the constellation of cytological radiation response programs
available and functioning within cells during the period of
damage recognition, repair, and fixation (26). Another
source of variation was found to be age of the donor.
Because the blood samples were irradiated extracorporally,
whatever effect the individuals’ body physiology could
have which could cause the age dependence, it would have
to be made prior to blood accrual. It seems more probable
that the age dependence of the cells is related either to a
programmed epigenetic effect or to an age-dependent dam-
age accumulation during lymphocyte development in the
host. Both of these examples, cell type and donor age,
demonstrate how important noninherited factors can be in
influencing apoptotic yield in leukocytes.
Two genetic sources of differences in apoptotic yield
were also observed, genetic disease and cryptic hypersen-
sitivity. The radiation reaction of patients with ataxia telan-
giectasia and ICF syndrome (5) both emphasize the role
genetic diseases can play. Furthermore, the retrospective
study of T-lymphocytes from patients who displayed en-
hanced toxicity to radiation therapy (cryptic hypersensitiv-
ity) clearly demonstrated a compromised apoptotic response
specific to these patients. The cohort consistently displayed
less radiation-induced apoptosis (on average 21.8 s, see
Fig. 5) than expected from age-matched controls. Eleven of
the hypersensitive responses were more than one standard
deviation below the mean. All of the hypersensitive patients
had a previous history of radiation exposure, and 6 dis-
played enhanced levels of background apoptosis associated
with concomitant chemotherapy; however, neither of these
factors significantly influenced apoptotic response to the
radiation doses employed in the leukocyte apoptosis assay.
Apoptosis is believed to protect an organism from the
inflammatory effects of necrosis by offering an autonomous
death mechanism; a physiologically accommodating and
programmed response induced by appropriate and antici-
pated signals (27). Apoptosis protects from inflammation in
a second manner. Apoptotic cells have been demonstrated to
induce release of anti-inflammatory cytokines such as inter-
leukin 10 (28). This suggests that enhanced inflammatory
reactions to radiotherapy associated with radiosensitivity, as
described in this study, arise not only from reduced apopto-
sis and subsequent enhanced necrosis, but also from con-
founding effects resulting from the reduced apoptosis, in-
cluding failure to induce release of anti-inflammatory
cytokines. Activation of the complex radiation-induced ap-
optosis program in nonstimulated peripheral blood lympho-
cytes is thought to result from initial damage to the DNA
and not residual damage (29, 30). Such programs consist of
three phases: damage recognition, intracellular signaling,
and actuation of response (26). During any one of these
three phases, modification of the function or the levels of
proteins which participate in the induction of apoptosis;
such as ATM, p53, Bcl-2, bax, the various caspases, etc., is
expected to interfere with the apoptotic yield. Because cel-
lular programs are so complex, until appropriate test meth-
ods become available, diagnostic assays should certainly
include tests of cellular response with which to substantiate
results from protein and gene studies.
There are two important unanswered questions which
need to be addressed. The first question concerns correla-
tions with other diagnostic tests of radiosensitivity (13, 31).
The validity of any diagnostic procedure can only be veri-
fied if some “gold standard” exists, in which case results of
the procedure are gauged against this (3). Unfortunately, if
no such appropriate “gold standard” exists, indirect indica-
tors must be taken. The leukocyte apoptosis assay very
clearly demonstrates an age dependence of apoptosis induc-
tion. If alternative assays with which this one could be
compared do not display a similar age dependence, either
they are measuring some other phenomenon or they are
simply not as reliable. In either case, their use as a “gold
standard” for testing the leukocyte apoptosis assay is ques-
tionable. It will, nevertheless, be of interest to compare the
leukocyte apoptosis assay with “gold standard” assays of
patient radiosensitivity as these become available.
The second question concerns the clinical endpoint of
interest. The leukocyte apoptosis assay was developed to
predict those patients who would display acute toxicity to
radiation therapy. This was a modest goal. It is readily
apparent to workers in the field of radiation oncology that
late toxicity is the more important parameter limiting dose
to the treated volume and the probability of disease-free
cure (32). It is intriguing, therefore, that four patients in-
cluded in the hypersensitive cohort (numbers 2, 5, 6, and 11)
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displayed both significantly reduced levels of apoptosis and
severe late effects. Furthermore, all nine ataxia telangiecta-
sia patients displayed significantly reduced levels of apo-
ptosis. We hope that the leukocyte apoptosis assay will
provide an indication of the expected magnitude of patient-
specific late toxicities. The assay also efficiently demon-
strates sensitizing effects of concomitant chemotherapy on
the background apoptosis levels in T-lymphocytes. Finally,
it is noted that with the increasing number of “dose-escala-
tion” clinical trials, using either conformal radiation therapy
or intensity modulated radiation therapy at various sites, the
radiation oncologist will welcome a simple and quick nor-
mal-tissue radiosensitivity test for use in determining eligi-
bility or stratification criteria of patients to be included in
such studies (5). As part of an ongoing prospective clinical
trial, these various issues are currently being addressed.
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